LFLeslie Astrid De la Fuente

Leslie Astrid De la Fuente

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leslie Astrid De la Fuente has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hipersensibilidad a medios de contraste yodado: estrategias diagnósticas y terapéuticas. Posicionamiento del Comité de Alergia a Medicamentos de Colegio Mexicano de Inmunología Clínica y Alergia

    by Rosalaura Virginia Villarreal González, Nataly Anais Flores García, Leslie Astrid De la Fuente, Alira Fraga Olvera, Anabel Ávila Lara, Ana Judith Montiel Sierra, Angelina Ingrid Robledo Martínez, Carlos Alberto Correa Serrano, Carolina Garcia Rosas, César Daniel Alonso Bello, et al.

    ANTECEDENTES: Las reacciones de hipersensibilidad a medios de contraste yodados representan un problema clínico relevante debido al uso creciente para estudios radiodiagnósticos. Estas reacciones se clasifican en inmunológicas inmediatas, no inmediatas y no inmunológicas, con una prevalencia variable y potenciales consecuencias graves (anafilaxia o reacciones adversas cutáneas graves). La identificación de factores de riesgo, clasificación y mecanismos inmunológicos de los medios de contraste permiten establecer estrategias de prevención y tratamiento. OBJETIVO: Analizar las características químicas de los medios de contraste, mecanismos inmunológicos y métodos diagnósticos disponibles, con la finalidad de establecer estrategias efectivas para su prevención, diagnóstico y tratamiento en poblaciones generales y vulnerables. MÉTODOLOGÍA: Se efectuó una revisión bibliográfica donde se analizaron los diferentes tipos de medios de contraste, según su estructura química, osmolaridad, osmolalidad y viscosidad, destacando su asociación con el riesgo de reacciones de hipersensibilidad. Se describen los mecanismos inmunológicos implicados, incluyendo respuestas mediadas por IgE, células T y el receptor MRGPRX2. Se detallan métodos diagnósticos: estudios in vivo e in vitro, y prueba de exposición controlada, evaluando la sensibilidad, especificidad y utilidad clínica. Se puntualiza la reactividad cruzada entre medios de contraste y la utilidad de agruparlos según sus características químicas para elegir alternativas seguras. Finalmente, se abordan estrategias terapéuticas y preventivas, como la premedicación, la selección del medio de contraste y las consideraciones especiales en poblaciones vulnerables (pacientes pediátricos, mujeres embarazadas y adultos mayores). CONCLUSIONES: La hipersensibilidad a medios de contraste requiere un enfoque diagnóstico y terapéutico multidisciplinario, basado en la adecuada caracterización de la reacción, estudios inmunológicos y selección personalizada del medio de contraste que de administrará. El conocimiento actual permite reducir significativamente la recurrencia de reacciones de hipersensibilidad mediante la sustitución del agente implicado y/o premedicación, optimizando así la seguridad de los procedimientos diagnósticos asociados con medios de contraste. PALABRAS CLAVE: Medios de contraste yodados; Anafilaxia; Prevalencia; Factores de riesgo; Poblaciones vulnerables; Osmolaridad; IgE; Células T; Prueba in vitro; Pacientes pediátricos; Mujeres embarazadas; Hipersensibilidad; Premedicación.

  • Open Access

    Delayed hypersensitivity reactions to taxanes: Clinical presentation and outcomes of post-medication and rapid drug desensitization

    by Rosalaura Villarreal-González, Leslie Astrid De la Fuente, Alexia Moreno-Silvestre, María Guadalupe Durán-Hernández, Diego Armando Sánchez-Alvarado, David Hernández-Barajas, Oscar Vidal-Gutiérrez


  • Innovative strategies for cisplatin desensitization in hyperthermic intraperitoneal chemotherapy of ovarian cancer

    by Rosalaura Villarreal-González, Eduardo Navarro-Bahena, Diana Cadenas-García, Leslie De la Fuente, Oscar Vidal-Gutiérrez

    We present a case of a 41-year-old female diagnosed with Granulosa Cell Tumor (GCT) EC IVB who developed a hypersensitivity reaction (HSR) to carboplatin during the sixth cycle of treatment and subsequently underwent successful intraperitoneal desensitization with cisplatin during hyperthermic intraperitoneal chemotherapy (HIPEC). The patient experienced a severe HSR 30 min after carboplatin infusion, presenting with generalized rash, pruritus, nausea, chest pain, and dyspnea. The infusion was halted, and she was treated with intramuscular epinephrine (0.50 mg), intravenous chloropyramine (20 mg), and 250 mL saline, resolving symptoms. Platinum skin tests were subsequently performed and yielded negative results for carboplatin, cisplatin, and oxaliplatin. Following multidisciplinary consensus, cytoreductive surgery with HIPEC and intraperitoneal desensitization to cisplatin was planned. The patient had a peritoneal carcinomatosis index (PCI) of 17. Cytoreductive surgery included omentectomy, appendectomy, resection of mesenteric implants, diaphragmatic and parietal peritonectomy, in bloc hysterectomy, bilateral salpingo-oophorectomy, and pelvic peritonectomy, achieving a completeness of cytoreduction (CC-0). HIPEC was performed with cisplatin (100 mg/m²) at 42°C for 140 min. A desensitization protocol with intraperitoneal cisplatin (180 mg in 8 incremental steps over 140 min) was successfully completed without adverse reactions. Platinum-based chemotherapeutics are frequently associated with HSR, with increasing incidence upon repeated exposure. Intraperitoneal administration, as in HIPEC, may reduce systemic hypersensitivity risks. While prior cases have demonstrated safe HIPEC administration of cisplatin in patients with oxaliplatin-induced HSR, no documented cases exist of intraperitoneal drug desensitization in this context. Our case suggests that intraperitoneal desensitization with cisplatin may be a viable alternative for patients with systemic HSR to platinum agents. Further research is required to establish safety protocols, cross-reactivity risks, and efficacy outcomes for this approach.


  • Dexamethasone desensitization in type III hypersensitivity reaction and multiple myeloma

    by Rosalaura Villarreal-González, Leslie Astrid de la Fuente, Diana Laura García-Soto, Mónica Elizabeth Hodoyan-Leal, Ana Laura Varela-Constantino, Andrés Gómez-De León, Oscar Vidal-Gutiérrez

    Introduction: Multiple myeloma (MM) is a hematologic cancer characterized by the accumulation of monoclonal plasma cells in the bone marrow. Dexamethasone is included in preferred regimens for primary therapy for both transplant-eligible and transplant-ineligible candidates. To date, type III hypersensitivity reactions to dexamethasone have not been previously reported. Case report: A 61-year-old man diagnosed with multiple myeloma received treatment with bortezomib and dexamethasone, achieving complete remission. In 2017, he experienced his first relapse and was managed with bortezomib, thalidomide, and dexamethasone. In 2019, his regimen was changed to carfilzomib, which was subsequently discontinued due to hematologic toxicity. In 2022, he presented with relapse and an ankle fracture, leading to the suspension of treatment. In 2023, carfilzomib and dexamethasone were restarted at lower doses. During intravenous and oral dexamethasone treatment, the patient developed skin lesions on his lower extremities, and, following evaluation by the Allergy and Immunology team, drug-induced vasculitis was diagnosed. Management and outcome: Given the need to reintroduce dexamethasone due to the lack of alternative therapeutic options, a dexamethasone desensitization protocol was implemented. A 5-step delayed desensitization protocol was successfully performed, with no reactivation of vasculitic lesions. Discussion: Although desensitization is generally contraindicated in type III hypersensitivity reactions, no prior cases of successful desensitization in dexamethasone-induced vasculitis have been reported. This is the first reported case of successful desensitization in a patient with dexamethasone-induced vasculitis. A limitation of this case report is that the mechanisms underlying drug tolerance remain unknown.


  • Hypersensitivity reactions to chemotherapy and biologics: Outcomes and safety of 927 desensitization in Mexico

    by Rosalaura Villarreal-González, Leslie Astrid De la Fuente, Diana Cadenas-García, Itzayana Ortega-Franco, Marianela Madrazo-Morales, Kathia Sáenz-Cantú, Meryl Cadena-Rosales, Rafael Piñeiro Retif, Oscar Vidal-Gutiérrez

    Introduction: Chemotherapy and monoclonal antibodies are increasingly associated with hypersensitivity reactions (HSRs), including anaphylaxis. Desensitization modulates allergic responses to drugs, facilitating temporary tolerance to full therapeutic doses. Methods: Observational, descriptive, ambispective study from August 2020 to August 2024, including cancer patients who came for treatment administration and developed a hypersensitivity reaction, and underwent 3-bag 12-step desensitization in 5.67 h. Demographic variables, atopic and oncological history, hypersensitivity reactions, breakthrough reactions (BTR) during desensitization, and safety of the protocols were reported. Results: 927 desensitization in 219 patients, 20.7% with personal atopy and 84% female. The most common oncological diagnoses were: breast cancer (23.3%), ovarian (22.1%), and cervical (15.9%). The drugs of the most hypersensitivity reactions were Paclitaxel 372 (40.2%), Carboplatin 172 (18.7%), Oxaliplatin 66 (7.1%), Docetaxel 59 (6.4%), Rituximab 40 (4.3%) and Trastuzumab 40 (4.3%). The most frequent hypersensitivity reactions were cutaneous 172 (18.6%), respiratory 173 (18.7%) and cardiovascular 165 (17.8%) with a severity scale of Brown I 12.1%, Brown II 43.3% and Brown III 44.6%. During desensitization 80/927 cases (8.6%) had breakthrough reactions: cutaneous 56 (6%), respiratory 18 (1.9%) and cardiovascular 17 (1.8%), of which the majority were mild reactions. All patients completed their desensitization with no deaths reported. Conclusions: Our study reports that patients undergoing desensitization protocols had a lower percentage of breakthrough reactions compared to the previous hypersensitivity reactions, showing that this procedure is safe and effective to continue first-line oncological treatment.